A United States–based Nigerian nurse practitioner and oncology researcher, Edith Declan, has called on the Federal Government ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

The Life and Artwork of Mago Gándara brings together more than 100 items, including oil paintings, watercolors, sculptures, drawings, photographs and personal writings.

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu. The company said it ...